Elzonris (tagraxofusp-erzs) — coverage criteria for BPDCN
Customize your policy alerts
Sign up for Anthem Policy CC-0088 alerts
Get alerted when Policy CC-0088 changes without checking for updates manually.
Monitor payer policy activity
Criteria governing medical-benefit coverage and prior authorization for Elzonris (tagraxofusp-erzs) for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including eligibility, dosing prerequisites, and monitoring requirements for providers and payers.
Updated criteria to reflect NCCN 2A recommendations for place in therapy and removed ECOG score requirement.
Wording and formatting criteria updates; coding reviewed with no changes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.